Windlas lifts dividend to ₹6.30 as profit rises 9% in FY26
Revenue grew 19% to ₹9,041M; profit touched ₹664M. Both numbers were in line with expectations.
— 3 earlier stories on Windlas Biotech Ltd. → ₹6.30 per share Dividend recommended (126% of face value)
What's new
- Dividend raised to ₹6.30 vs ₹5 last year.
- Revenue up 19% YoY, net profit up 9%.
- Results were widely anticipated; no surprises.
Why it matters
The dividend increase signals confidence, but the results were already priced in after prior guidance and buyback. For a micro-cap pharma, steady execution is expected; this filing doesn't alter the thesis.
What we're watching
- Next quarter's revenue trajectory.
- Any signal on capex or new product launches.
- Whether the buyback completion affects float.
The full read
Windlas posted predictable numbers for FY26—₹9,041M revenue, ₹664M profit—in line with guided expectations. The dividend bump to ₹6.30 is a small positive but not a surprise. With no deviation from anticipated performance, the filing confirms the existing narrative without adding trading torque.
Mentioned: ₹6.30 dividend · FY26 revenue ₹9,041M · net profit ₹664M
Primary source BSE filings for WINDLAS NSE filings for WINDLAS Research WINDLAS on Tijori Finance Our reading is derived from the exchange filing. Verify on the exchange before acting.